Organon’s attempt to revive a once-rejected “natural” contraceptive is over, a spokesperson confirmed to Endpoints News.
The Merck women’s health spinoff has terminated a Phase III trial for NOMAC-E2 early due to “business reasons,” the spokesperson said. The company said the decision was unrelated to the drug’s safety.
NOMAC-E2 was developed by Theramex, a women’s health business that was once part of Merck KGaA and Teva. The candidate has been touted as a “natural” alternative to other contraceptives using synthetic estrogen, because it contains a version of the hormone that’s structurally identical to estrogen produced in the body.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.